Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Alberta
$27,000.00
Uncovering the role of PAR-Binding motifs in MAEA-Mediated DNA repair and PARP inhibitor Sensitivity
EF 2025-26
Résumé
High-grade serous ovarian cancer is the deadliest form of ovarian cancer, and although PARP inhibitor (PARPi) drugs have improved treatment, many patients eventually stop responding to the current front line treatments. Thus, to improve long-term outcomes, it is essential to understand the mechanisms driving PARPi resistance and to develop reliable predictors of patient response. Our research focuses on a protein called MAEA, which our lab recently discovered plays an important role in how cells repair DNA damage. We found that when MAEA is removed from PARPi-resistant ovarian cancer cells, the cancer becomes sensitive to these drugs again. MAEA also binds to a small molecule called PAR, which we believe helps coordinate DNA repair. We have identified two specific regions within MAEA that may control this binding, but their roles are not yet understood. This project will test whether these regions are needed for MAEA to function in DNA repair and to influence how cancer cells respond to PARPi. Using paired ovarian cancer cell lines taken from the same patient before and after developing drug resistance, we plan to: 1- Track how normal and mutant forms of MAEA (mutants that disrupt PAR-binding regions) accumulate at the sites of DNA damage to see whether these regions are required for MAEA to respond properly to DNA damage. 2- Measure how well cells activate their DNA repair systems when these regions in the MAEA protein are disrupted. 3- Test whether disrupting PAR-binding regions makes cancer cells more sensitive to PARPi. By revealing how MAEA helps cancer cells survive PARPi treatment, this research may identify new drug targets that could make PARPi therapies more effective for patients with ovarian cancer.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572891
Name
Al-Sheikh-Ali Rama
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Uncovering the role of PAR-Binding motifs in MAEA-Mediated DNA repair and PARP inhibitor Sensitivity
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Chemotherapy Resensitization; Dna Damage Response; Dna Repair; High-Grade Serous Ovarian Carcinoma; Homologous Recombination; Maea; Ovarian Cancer; Ovarian Cancer Biomarkers; Parp Inhibitor Resistance; Parp Inhibitors
Abstract
High-grade serous ovarian cancer is the deadliest form of ovarian cancer, and although PARP inhibitor (PARPi) drugs have improved treatment, many patients eventually stop responding to the current front line treatments. Thus, to improve long-term outcomes, it is essential to understand the mechanisms driving PARPi resistance and to develop reliable predictors of patient response. Our research focuses on a protein called MAEA, which our lab recently discovered plays an important role in how cells repair DNA damage. We found that when MAEA is removed from PARPi-resistant ovarian cancer cells, the cancer becomes sensitive to these drugs again. MAEA also binds to a small molecule called PAR, which we believe helps coordinate DNA repair. We have identified two specific regions within MAEA that may control this binding, but their roles are not yet understood. This project will test whether these regions are needed for MAEA to function in DNA repair and to influence how cancer cells respond to PARPi. Using paired ovarian cancer cell lines taken from the same patient before and after developing drug resistance, we plan to: 1- Track how normal and mutant forms of MAEA (mutants that disrupt PAR-binding regions) accumulate at the sites of DNA damage to see whether these regions are required for MAEA to respond properly to DNA damage. 2- Measure how well cells activate their DNA repair systems when these regions in the MAEA protein are disrupted. 3- Test whether disrupting PAR-binding regions makes cancer cells more sensitive to PARPi. By revealing how MAEA helps cancer cells survive PARPi treatment, this research may identify new drug targets that could make PARPi therapies more effective for patients with ovarian cancer.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Al-Sheikh-Ali, Rama
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~